Cognition Therapeutics (NASDAQ:CGTX)
- Number of Upgrades from Top-Ranked Analysts
- 4 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $7.13 (1,498.3% Upside)
About Cognition Therapeutics
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
More about Cognition Therapeutics
Recent Analyst Ratings
